Analyst picks & changes

Cephalon Inc.

(CEPH)

In anticipation of today's announcement of Phase II/III results of Myotrophin

IGF-1

in amyotrophic lateral sclerosis, Oppenheimer's Geller initiated coverage of CEPH with a "market perform"

Read the full 301 word article

How to gain access

Continue reading with a
two-week free trial.